A Trial to Evaluate the Superior Mesenteric Vein (14V) Lymphadenectomy for Distal Advanced Gastric Cancer
NCT ID: NCT02272894
Last Updated: 2015-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
510 participants
OBSERVATIONAL
2014-07-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
D2 Radical Gastrectomy Adding Dissection of the Superior Mesenteric Vein Lymph Node
Dissection of the Superior Mesenteric Vein Lymph Node
14v lymph node dissection
Group B
D2 Radical Gastrectomy
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dissection of the Superior Mesenteric Vein Lymph Node
14v lymph node dissection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Physical condition and organ function allows to tolerable abdominal surgery;
* Willing and able to comply with the program during the study period;
* Aged 18 to 70 years, preoperative gastric cancer patients with pathologically confirmed;
* With more than a 6-month life expectancy;
* No other serious concomitant diseases;
* No adjuvant chemotherapy before recurrence;
* Karnofsky performance status scale ≥ 60;
* All patients accept 6 cycles XELOX chemotherapy regimen
Exclusion Criteria
* Women of childbearing age do not take contraceptive measures;
* Organ transplantation patients need immunosuppressive therapy;
* Five years after the trial begin,other malignant tumor occur;
* While using other experimental drug or other clinical trials are being;
* Can not take oral medications;
* Mentally disordered;
* Severe recurrent infections were not controlled or with other serious concomitant diseases;
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital with Nanjing Medical University
OTHER
Shanxi Province Cancer Hospital
OTHER
Peking University Cancer Hospital & Institute
OTHER
Qingdao University
OTHER
Fudan University
OTHER
Sun Yat-sen University
OTHER
Harbin Medical University
OTHER
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER
The First Affiliated Hospital of Dalian Medical University
OTHER
Qinghai University
OTHER
Second Hospital of Jilin University
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Wulumuqi General Hospital of Lanzhou Military Command
OTHER
Shandong Provincial Hospital
OTHER_GOV
Nanjing PLA General Hospital
OTHER
Tianjin Medical University Cancer Institute and Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Han Liang, Master
Role: PRINCIPAL_INVESTIGATOR
Tianjin Medical University Cancer Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Hospital
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Liang Han, Master
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Yang QC, Zhou HK, Yue C, Wang WD, Gao RQ, Mo ZC, Ji PP, Wei JP, Yang XS, Yu PF, Li XH, Ji G. [The correlation between No. 6 and No. 14v lymph node metastasis and the value of dissecting these lymph nodes in radical gastrectomy]. Zhonghua Wei Chang Wai Ke Za Zhi. 2023 Jan 25;26(1):38-43. doi: 10.3760/cma.j.cn441530-20221123-00491. Chinese.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E201419A
Identifier Type: -
Identifier Source: org_study_id